SOHO State of the Art Updates and Next Questions:Harnessing Apoptosis in AML

Kapil Saxena; Courtney DiNardo; Naval Daver; Marina Konopleva

doi:10.1016/j.clml.2021.08.015

SOHO State of the Art Updates and Next Questions:Harnessing Apoptosis in AML

Kapil Saxena, Courtney DiNardo, Naval Daver, Marina Konopleva

Leukemia

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Abstract

The treatment landscape for acute myeloid leukemia has expanded significantly in the past 5 years with the approval of several therapeutic small molecules. While agents such as FLT3 inhibitors and IDH inhibitors are restricted for patients with specific mutations, the selective BCL-2 inhibitor venetoclax combined with a hypomethylating agent or low-dose cytarabine was approved after demonstrating frontline efficacy across a molecularly heterogenous group of patients. Currently, venetoclax is being investigated in combination with multiple other therapies as the role of the intrinsic apoptotic pathway in acute myeloid leukemia continues to be explored.

Original language	English (US)
Pages (from-to)	133-139
Number of pages	7
Journal	Clinical Lymphoma, Myeloma and Leukemia
Volume	22
Issue number	3
DOIs	https://doi.org/10.1016/j.clml.2021.08.015
State	Published - Mar 2022

Keywords

BCL-2
BCL-XL
MCL-1
Synergy
Venetoclax

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1016/j.clml.2021.08.015

Cite this

@article{4376085d6ca84819a88ceee1d7b38563,

title = "SOHO State of the Art Updates and Next Questions:Harnessing Apoptosis in AML",

abstract = "The treatment landscape for acute myeloid leukemia has expanded significantly in the past 5 years with the approval of several therapeutic small molecules. While agents such as FLT3 inhibitors and IDH inhibitors are restricted for patients with specific mutations, the selective BCL-2 inhibitor venetoclax combined with a hypomethylating agent or low-dose cytarabine was approved after demonstrating frontline efficacy across a molecularly heterogenous group of patients. Currently, venetoclax is being investigated in combination with multiple other therapies as the role of the intrinsic apoptotic pathway in acute myeloid leukemia continues to be explored.",

keywords = "BCL-2, BCL-XL, MCL-1, Synergy, Venetoclax",

author = "Kapil Saxena and Courtney DiNardo and Naval Daver and Marina Konopleva",

note = "Publisher Copyright: {\textcopyright} 2021 The Authors",

year = "2022",

month = mar,

doi = "10.1016/j.clml.2021.08.015",

language = "English (US)",

volume = "22",

pages = "133--139",

journal = "Clinical Lymphoma, Myeloma and Leukemia",

issn = "2152-2650",

publisher = "Cancer Media Group",

number = "3",

}

TY - JOUR

T1 - SOHO State of the Art Updates and Next Questions:Harnessing Apoptosis in AML

AU - Saxena, Kapil

AU - DiNardo, Courtney

AU - Daver, Naval

AU - Konopleva, Marina

PY - 2022/3

Y1 - 2022/3

N2 - The treatment landscape for acute myeloid leukemia has expanded significantly in the past 5 years with the approval of several therapeutic small molecules. While agents such as FLT3 inhibitors and IDH inhibitors are restricted for patients with specific mutations, the selective BCL-2 inhibitor venetoclax combined with a hypomethylating agent or low-dose cytarabine was approved after demonstrating frontline efficacy across a molecularly heterogenous group of patients. Currently, venetoclax is being investigated in combination with multiple other therapies as the role of the intrinsic apoptotic pathway in acute myeloid leukemia continues to be explored.

AB - The treatment landscape for acute myeloid leukemia has expanded significantly in the past 5 years with the approval of several therapeutic small molecules. While agents such as FLT3 inhibitors and IDH inhibitors are restricted for patients with specific mutations, the selective BCL-2 inhibitor venetoclax combined with a hypomethylating agent or low-dose cytarabine was approved after demonstrating frontline efficacy across a molecularly heterogenous group of patients. Currently, venetoclax is being investigated in combination with multiple other therapies as the role of the intrinsic apoptotic pathway in acute myeloid leukemia continues to be explored.

KW - BCL-2

KW - BCL-XL

KW - MCL-1

KW - Synergy

KW - Venetoclax

UR - http://www.scopus.com/inward/record.url?scp=85116141078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85116141078&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2021.08.015

DO - 10.1016/j.clml.2021.08.015

M3 - Review article

C2 - 34602371

AN - SCOPUS:85116141078

SN - 2152-2650

VL - 22

SP - 133

EP - 139

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

IS - 3

ER -

SOHO State of the Art Updates and Next Questions:Harnessing Apoptosis in AML

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this